Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Waldenstrom Macroglobulinemia 1Paraproteinemias 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Hemostatic Disorders 1Hematologic Diseases 1

Interventions

Cyclophosphamide 14fludarabine 12fludarabine phosphate 8Melphalan 8Brentuximab Vedotin 8Whole-Body Irradiation 7Mycophenolic Acid 7Busulfan 7Rituximab 6Tacrolimus 5Lenalidomide 4Etoposide 4isatuximab 3Sirolimus 3Mesna 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3pembrolizumab 2nilotinib 2dacetuzumab 2Vincristine 2Thiotepa 2Sugars 2Stem Cell Transplantation 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Ondansetron 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Diseases × epratuzumab × Clear all
NCT00113802 2021-08-19

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Gilead Sciences

Phase 2 Terminated
31 enrolled
Lymphoid

Hematologic Diseases, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Paraproteinemias, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡